Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) ( Lp (a) ) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys.
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > LDLR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.